The present study extends and supports our previous findings in glioma cells, identifying several key metabolic pathways that are affected by the CcO regulatory subunit COX4 isoform expressed and may underlie the clinical progression and development of therapeutic resistance in GBM. This evidence concerns the gene RYR1 and glioma.